Tag: proxy

PHOENIX, July 23, 2025 (GLOBE NEWSWIRE) -- Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) announced that it filed a registration statement on Form S-4 and S-1 with the U.S. Securities and Exchange Commission (“SEC”) on July 10, 2025 in connection with the Company's proposed merger (the “Merger”) with Republic Airways Holdings Inc. (“Republic”). The registration statement includes a proxy statement and preliminary prospectus. Once declared effective by the SEC, the final proxy statement/prospectus included in the Form S-4/Form S-1 will be mailed to the Mesa stockholders prior to their vote on the proposed Merger.

WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”).  

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Broadmark Realty Capital Inc. (“Broadmark” or “the Company”) (NYSE: BRMK), Ready Capital Corporation ("Ready Capital") (NYSE: RC), and certain officers.

BROOKLYN, New York , July 19, 2025 (GLOBE NEWSWIRE) -- LTESocks.io, a leading provider of high-performance mobile proxy solutions, today announced its ambitious 2025 technology roadmap designed to build the next generation of network infrastructure for its global client base. The multi-phase initiative focuses on fundamentally enhancing speed, reliability, and scalability by integrating cutting-edge protocols and expanding its state-of-the-art 5G network.

CHARLOTTE, N.C. and STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- HCM II Acquisition Corp., (Nasdaq: HOND), (“HCM II”), a special-purpose acquisition company and Terrestrial Energy Inc., (“Terrestrial Energy”), a developer of small modular nuclear plants using advanced reactor technology, today announced the filing of the draft registration statement on Form S-4 with the U.S. Securities and Exchange Commission (“SEC”).

Revised Potential Distribution Range of $0.03 to $0.07 per share
based on current estimates and assumptions

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.